Carolyn M. Setze

1.7k total citations
47 papers, 1.3k citations indexed

About

Carolyn M. Setze is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Carolyn M. Setze has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 23 papers in Endocrinology, Diabetes and Metabolism and 15 papers in Epidemiology. Recurrent topics in Carolyn M. Setze's work include Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (22 papers) and Hepatitis C virus research (15 papers). Carolyn M. Setze is often cited by papers focused on Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (22 papers) and Hepatitis C virus research (15 papers). Carolyn M. Setze collaborates with scholars based in United States, Japan and Canada. Carolyn M. Setze's co-authors include Maureen T. Kelly, James C. Stolzenbach, Darryl J. Sleep, Edward Tam, Susan M. Buttler, Regis A. Vilchez, Peter H. Jones, Prajakta Badri, Wangang Xie and Michael H. Davidson and has published in prestigious journals such as New England Journal of Medicine, Hepatology and Diabetes Care.

In The Last Decade

Carolyn M. Setze

47 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carolyn M. Setze United States	19	724	615	477	349	237	47	1.3k
Eleni Theocharidou United Kingdom	22	859 1.2×	1.0k 1.7×	538 1.1×	334 1.0×	52 0.2×	49	1.8k
Yee‐Kit Tse Hong Kong	30	1.9k 2.7×	2.3k 3.7×	242 0.5×	225 0.6×	201 0.8×	87	2.7k
Juan Ignacio Arenas Spain	18	386 0.5×	637 1.0×	223 0.5×	92 0.3×	58 0.2×	44	1.2k
Térésa Antonini France	20	908 1.3×	856 1.4×	333 0.7×	112 0.3×	118 0.5×	69	1.8k
Katherine Stuart Australia	23	834 1.2×	859 1.4×	253 0.5×	163 0.5×	58 0.2×	73	1.6k
Janice H. Jou United States	17	1.3k 1.9×	1.4k 2.3×	319 0.7×	256 0.7×	26 0.1×	43	2.1k
Leigh U. Horsfall Australia	21	785 1.1×	1.1k 1.9×	212 0.4×	265 0.8×	22 0.1×	49	1.4k
Michelle M. Richardson United States	12	571 0.8×	673 1.1×	299 0.6×	130 0.4×	13 0.1×	31	1.3k
Parvez Mantry United States	23	1.5k 2.0×	1.4k 2.3×	513 1.1×	196 0.6×	161 0.7×	83	2.1k
Gourdas Choudhuri India	24	219 0.3×	614 1.0×	856 1.8×	197 0.6×	170 0.7×	82	1.7k

Countries citing papers authored by Carolyn M. Setze

Since Specialization

Citations

This map shows the geographic impact of Carolyn M. Setze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carolyn M. Setze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carolyn M. Setze more than expected).

Fields of papers citing papers by Carolyn M. Setze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carolyn M. Setze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carolyn M. Setze. The network helps show where Carolyn M. Setze may publish in the future.

Co-authorship network of co-authors of Carolyn M. Setze

This figure shows the co-authorship network connecting the top 25 collaborators of Carolyn M. Setze. A scholar is included among the top collaborators of Carolyn M. Setze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carolyn M. Setze. Carolyn M. Setze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gane, Edward, Fred Poordad, Neddie Zadeikis, et al.. (2019). Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease. Clinical Infectious Diseases. 69(10). 1657–1664. 23 indexed citations

Sato, Ken, Kazuaki Chayama, Katia Alves, et al.. (2017). Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Advances in Therapy. 34(6). 1449–1465. 9 indexed citations

Kwo, Paul Y., Parvez Mantry, Eoin Coakley, et al.. (2014). An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine. 371(25). 2375–2382. 297 indexed citations

Kwo, Paul Y., Parvez Mantry, Eoin Coakley, et al.. (2014). O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION. Journal of Hepatology. 60(1). S47–S47. 22 indexed citations

Davidson, Michael H., Robert S. Rosenson, Kevin C. Maki, et al.. (2012). Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. Cardiovascular Drugs and Therapy. 26(4). 349–358. 12 indexed citations

Lawitz, Eric, Andrew Campbell, Emily O. Dumas, et al.. (2012). 1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS. Journal of Hepatology. 56. S469–S470. 20 indexed citations

Roth, Eli M., Robert S. Rosenson, Peter H. Jones, et al.. (2012). Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies. Journal of clinical lipidology. 6(6). 534–544. 2 indexed citations

Langley, Richard G., Kim Papp, Alice B. Gottlieb, et al.. (2012). Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 27(10). 1252–1261. 56 indexed citations

Goldberg, Anne C., Vera Bittner, Carl J. Pepine, et al.. (2011). Efficacy of Fenofibric Acid Plus Statins on Multiple Lipid Parameters and Its Safety in Women With Mixed Dyslipidemia. The American Journal of Cardiology. 107(6). 898–905. 9 indexed citations

10.

Ballantyne, Christie M., Peter H. Jones, Maureen T. Kelly, et al.. (2011). Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides. Cardiovascular Drugs and Therapy. 25(1). 59–67. 12 indexed citations

11.

Ballantyne, Christie M., Michael H. Davidson, Carolyn M. Setze, & Maureen T. Kelly. (2011). Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L). Journal of clinical lipidology. 5(5). 401–407. 5 indexed citations

12.

Mohiuddin, Syed M., Kamlesh M. Thakker, Carolyn M. Setze, & Maureen T. Kelly. (2011). Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion. 27(5). 1067–1078. 6 indexed citations

13.

Roth, Eli M., Robert S. Rosenson, Dawn M. Carlson, et al.. (2010). Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study. Cardiovascular Drugs and Therapy. 24(5-6). 421–428. 20 indexed citations

14.

Pepine, Carl J., Terry A. Jacobson, Dawn M. Carlson, et al.. (2010). Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology. 33(10). 609–619. 7 indexed citations

15.

Kipnes, Mark, Eli M. Roth, Carolyn M. Setze, et al.. (2009). Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination. Clinical Drug Investigation. 30(1). 51–61. 18 indexed citations

16.

Jones, Peter J.H., Anne C. Goldberg, Howard R. Knapp, et al.. (2009). Abstract: 517 EFFICACY AND SAFETY OF FENOFIBRIC ACID IN COMBINATION WITH ATORVASTATIN AND EZETIMIBE IN PATIENTS WITH MIXED DYSLIPIDEMIA: A PHASE 3 STUDY. Atherosclerosis Supplements. 10(2). e262–e263. 1 indexed citations

17.

Jones, Peter H., Michael H. Davidson, Anne C. Goldberg, et al.. (2009). Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of clinical lipidology. 3(2). 125–137. 17 indexed citations

18.

Goldberg, Anne C., Harold Bays, Christie M. Ballantyne, et al.. (2008). Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. The American Journal of Cardiology. 103(4). 515–522. 58 indexed citations

19.

Jones, Peter H., Harold Bays, Michael H. Davidson, et al.. (2008). Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins. Clinical Drug Investigation. 28(10). 625–634. 34 indexed citations

20.

Bays, Harold, Peter H. Jones, Syed M. Mohiuddin, et al.. (2008). Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of clinical lipidology. 2(6). 426–435. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact